MSD closed 2023 with a turnover of 55.5 billion euros, 1% more than in 2022, when it obtained sales of 54.7 billion euros. The pharmaceutical company...
The Viennese biotech company has developed a type of vaccine based on genetically modified arenaviruses. In the case of HB-200, these are vectors based on the...